Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28914879 | 0.83 | PDE4A (0.46) | KDM4EGPR119PDE4APDE4BPDE4C | |
| SCHEMBL28586371 | 0.83 | PDE4A (0.46) | KDM4EGPR119PDE4APDE4BPDE4C | |
| SCHEMBL25292925 | 0.80 | MEN1 (0.47) | MEN1KMT2ASTS | |
| SCHEMBL20594536 | 0.80 | PDE4A (0.46) | KDM4EGPR119PDE4APDE4BPDE4C | |
| SCHEMBL16097475 | 0.80 | FPR2 (0.43) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3733957 | 0.80 | KDM4E (0.52) | KDM4EPKMGPR119MEN1KMT2A | |
| SCHEMBL3730368 | 0.80 | PDE4A (0.57) | KDM4EPKMGPR119PDE4APDE4B | |
| SCHEMBL1828425 | 0.79 | MCL1 (0.47) | MEN1KMT2AMCL1 | |
| SCHEMBL27504767 | 0.79 | STS (0.48) | KDM4EPKMGPR119STS | |
| SCHEMBL3741416 | 0.79 | STS (0.48) | KDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2318362-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | Theravance, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | KDM4E 667/4885PKM 394/4885GPR119 1182/4885 |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | KDM4E 667/4885PKM 394/4885GPR119 1182/4885 |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | KDM4E 667/4885PKM 394/4885GPR119 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.